Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rahima Jamal

Showing results (31-40 of 36) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 36 results.
European Journal of Cancer (Oxford, England : 1990)|June 5, 2023
Prognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanomaOliver John Kennedy, Michal Kicinski, Sara Valpione, et al.
European Journal of Cancer (Oxford, England : 1990)|February 25, 2024
Prognostic and predictive value of non-steroidal anti-inflammatory drugs in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanomaOliver John Kennedy, Nina Glassee, Michal Kicinski, et al.
Nature Medicine|July 6, 2023
Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trialBertrand Routy, John G Lenehan, Wilson H Miller, et al.
The Lancet. Oncology|April 15, 2021
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trialAndrew Bottomley, Corneel Coens, Justyna Mierzynska, et al.
Science Immunology|April 1, 2022
Spatially mapping the immune landscape of melanoma using imaging mass cytometryDan Moldoveanu, LeeAnn Ramsay, Mathieu Lajoie, et al.
Nature Medicine|January 28, 2026
Fecal microbiota transplantation plus immunotherapy in non-small cell lung cancer and melanoma: the phase 2 FMT-LUMINate trialSreya Duttagupta, Meriem Messaoudene, Sebastian Hunter, et al.
Pageof 4

Showing results (31-40 of 36) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 36 results.
European Journal of Cancer (Oxford, England : 1990)|June 5, 2023
Prognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanomaOliver John Kennedy, Michal Kicinski, Sara Valpione, et al.
European Journal of Cancer (Oxford, England : 1990)|February 25, 2024
Prognostic and predictive value of non-steroidal anti-inflammatory drugs in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanomaOliver John Kennedy, Nina Glassee, Michal Kicinski, et al.
Nature Medicine|July 6, 2023
Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trialBertrand Routy, John G Lenehan, Wilson H Miller, et al.
The Lancet. Oncology|April 15, 2021
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trialAndrew Bottomley, Corneel Coens, Justyna Mierzynska, et al.
Science Immunology|April 1, 2022
Spatially mapping the immune landscape of melanoma using imaging mass cytometryDan Moldoveanu, LeeAnn Ramsay, Mathieu Lajoie, et al.
Nature Medicine|January 28, 2026
Fecal microbiota transplantation plus immunotherapy in non-small cell lung cancer and melanoma: the phase 2 FMT-LUMINate trialSreya Duttagupta, Meriem Messaoudene, Sebastian Hunter, et al.
Pageof 4